TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Patient global satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean incremental plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximal incremental plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: annualized relapse score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-medication prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in pp70S6K
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIH-Chronic Prostatitis Symptom Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe ovarian hyperstimulation syndrome (SOHSS) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of oocytes recovered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy rates by embryo transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Marginal discrepancies after cementation for crowns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Pain Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 100% monthly response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of migraine headache-free periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major procedure-related adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in arteriole diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in assessment scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: significantly raised blood pressure
Endpoint domain: Adverse events/effects
Primary endpoint: Mean retinal thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static elastance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Minimal resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: spasm frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of P829 scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of P829 scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification or exclusion of malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total pulmonary resistance decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in mean pulmonary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lower risk of lethal prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Improved survival after diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in knowledge about inhalation therapy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of dry nights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pulpal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproduction of cranial and spine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total lordosis measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atazanavir hair concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for CVP system explantation and reimplantation
Endpoint domain: Adverse events/effects
Primary endpoint: System malfunction after FCS
Endpoint domain: Adverse events/effects
Primary endpoint: Combined score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increases in specific IgG(4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: time to become ventilator-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: prevention or resolution of bruising
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ocular infection reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Expression of ZO-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Expression of occludin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Expression of claudin-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: significant distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FRC reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chest radiograph abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: variability of sleep duration and night wake time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total amounts of pain medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: better outcome at the end of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: better outcome at 18 months of follow-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hCG-time relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: hs-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper limb and neck disability reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of symptoms of grief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Passive coping styles
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hip bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blanching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: difficulty of i.v. placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reemergence of sexual dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with sexual functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of throws applied
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SJFT index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year primary patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Fractional [1‐(13)C]phenylalanine oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Passive range of knee flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Response to phentolamine test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final spherical equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rate of pre-defined critical actions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported physical activity (PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in physical activity barriers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLPFC-left caudate connectivity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insertion torque value (ITV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apparent volume of distribution (V/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VI (velocity index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: t-score index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nocturnal spinal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall spinal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: favorable outcome reported by patients and observers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glycemic improvement (HOMA-IR mean change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: variceal recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variceal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Ease of the CT read
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in supragingival plaque levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in subgingival plaque levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of wheeze
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of allergic rhino-conjunctivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: self-reported dietary modification
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: force platform measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25-FWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-care knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: powerlessness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive Predictive Value (PPV) of diagnostic codes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mitochondrial damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast cancer screening knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: breast cancer screening beliefs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: maximum late fall in forced expiratory volume in 1 second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adhesions
Endpoint domain: Adverse events/effects
Primary endpoint: enforcement challenges of smoke-free rules
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: time to diagnostic resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients who reached diagnostic resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of erosive esophagitis relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GERD symptom recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of spinal pain incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of abdominal pain incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of quality of life indices
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Apnoea-hypopnoea events per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time spent in light sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stage shifts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychomotor and eye‐tracking impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in AaDO₂
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Remission (UCDAI score <= 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma renin activity (PRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma aldosterone (PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma atrial natriuretic peptide (ANP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean arterial pressure increase after intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 95% effective dose (ED95) for preventing hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cotinine-confirmed quit rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per additional QALY
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in KSC of lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of sites free of T. forsythensis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of sites free of P. gingivalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Transient neurologic deficit
Endpoint domain: Adverse events/effects
Primary endpoint: AD literacy levels
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overnight myofibrillar protein synthesis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peeling force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: SC removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: TEWL (transepidermal water loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease in low-density lipoprotein (LDL) cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BPD or death
Endpoint domain: Mortality/survival
Primary endpoint: Rate of discordant respiratory care orders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Average number of respiratory treatments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Respiratory care charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effectiveness in treating acute peptic ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety of ranitidine and nizatidine
Endpoint domain: Adverse events/effects
Primary endpoint: Mental health hospitalizations
Endpoint domain: Adverse events/effects
Primary endpoint: Intrahepatic lipid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average total monthly health care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Suppression of plasma HIV‐1 RNA to <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CD4 cell counts increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevention of AIDS‐defining events
Endpoint domain: Adverse events/effects
Primary endpoint: Probing bone level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual neoplasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PSA serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global illness perceptions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of feed intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Numerical Rating Scale pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in patient assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the receiver operator characteristics curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first-year maximal intimal thickness (MIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mean lumen area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mean vessel area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 30-day incidence of death, reinfarction, and recurrent angina
Endpoint domain: Mortality/survival
Primary endpoint: TIMI major hemorrhage rate
Endpoint domain: Adverse events/effects
Primary endpoint: Pregnancy rate within 1 year of randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic AIx change after NTG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BAD fold increase after NTG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Health screenings obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DHEAS levels in patients with SLE compared to controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hausdorff distances between predicted and ground truth contours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: registration speed of 0.5 s
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ORN at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: insertive UAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCAA/AAA ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of units of allogeneic blood transfused per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients receiving any blood product
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of influenza-specific Th1 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in NIHSS score from baseline to 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modified Rankin scale score at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: blood loss during liver parenchymal division
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: baseline APV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximal APV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mitigation of behavioral health issues
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cumulative morphine consumption at 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain scores at 4h and 6h after delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAD behavior prediction
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Number of nighttime awakenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALT concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: percentage of ALT values exceeding 40 U/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: fasting insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Volume of bony callus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time of external fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in ONSD measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Confirmed disability progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSIS-29 physical scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MSIS-29 psychological scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Negative culture results for fungal organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes